Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- PMDA to Start 2nd 5-Year Plan a Year Ahead of Schedule
January 22, 2007
- JGPMA Proposes New Drug Benefit System
January 22, 2007
- Reform of Review System a Top Priority for PFSB: Mr Takahashi
January 22, 2007
- MEDICAL DEVICE NEWS IN BRIEF
January 22, 2007
- REGULATORY NEWS IN BRIEF ―２―
January 15, 2007
- FY2007 Draft Budget Includes \68.8 Bil. to Promote Life Science R&D: MEXT
January 15, 2007
- Next Clinical Trial Promotion Plan to Be Announced By End of March
January 15, 2007
- UK DOH's Expert Group Issues Recommendations on First-in-man Trials of High-risk Agents
January 15, 2007
- R&D NEWS IN BRIEF
January 15, 2007
- 10 Questions for the New Year
January 15, 2007
- Asymptomatic Hepatitis B 57% : Bristol-Myers
January 15, 2007
- Seminar
January 15, 2007
- Korosho to Initiate "Purity Testing" Project for Generics
January 15, 2007
- Blopress Remains Top Selling Drug for 3rd Year in a Row
January 15, 2007
- GENERIC NEWS IN BRIEF
January 15, 2007
- BUSINESS NEWS IN BRIEF
January 15, 2007
- OPINION
January 15, 2007
- Burgeoning Market for ARBs -Hot Battlefield for Megapharmas-
January 15, 2007
- Constipation Does Not Increase Risk of Colorectal Cancer: Korosho Study Group
January 15, 2007
- Korosho Committed to Promoting Innovation in Pharma Industry: Health Minister
January 15, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…